(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Of the patients who were eligible for breast conservation therapy (BCT), younger age and being married were associated with choosing mastectomy.

Adam S. Reese, MD, MS, S.B. Kesmodel, MD, J.B. Reese, PhD, E.C. Bellavance, MD, C. Campassi, MD, K.H. Tkaczuk, MD, T. Bao, MD, S.S. Chumsri, MD, J.A. Olsen, MD, S.J. Feigenberg, MD; University of Maryland Medical Center

Purpose and Objectives: To evaluate clinical factors associated with the choice of mastectomy in patients eligible for breast conservation therapy (BCT).

Materials and Methods: Between July 2009 and December 2011, a total of 208 women with invasive or noninvasive breast cancers were evaluated in a multidisciplinary breast cancer program at the University of Maryland and underwent surgery. Patients with lobular carcinoma in situ (LCIS) and atypical histologies (ie, lymphoma, sarcoma, and phyllodes) were excluded. A total of 131 who were eligible for BCT were analyzed for factors that predicted patient choice of surgery. We used Fisher’s exact test and likelihood ratio to examine whether choice of surgery (mastectomy vs BCT) differed by clinical characteristics (eg, age [< 60 vs ≥ 60 y], race [white vs black vs other], family history [yes vs no], marital status [married vs unmarried], clinical T-stage [Tis vs T1 vs T2], N-stage [N1–2 vs N0], group stage [stage 0–1 vs stage 2–3], histology [DCIS vs invasive ductal cancer (IDC) vs invasive lobular cancer (ILC)], bilateral disease [yes vs no], and previous breast cancer [yes vs no]).

Results: Among the 208 patients who had mastectomy (n = 106), after advanced disease (T3/T4; n = 32), patient choice was the second most commonly cited reason for undergoing mastectomy (n = 29). Other reasons included poor expected cosmesis (n = 23), multicentric disease (n = 15), prior radiation (n = 5), and persistently positive margins (n = 2). Eleven patients who were initially deemed eligible for breast conservation were rendered ineligible after magnetic resonance imaging (MRI) findings showed multicentricity or tumor size > 5 cm.

Twenty-nine of 131 patients were deemed eligible for BCT by their multidisciplinary team; yet, 29 chose mastectomy. Results of the Fisher’s exact and likelihood ratio tests showed that choice of surgery differed significantly by age and marital status. Specifically, patients were more likely to choose mastectomy if they were younger (< 60 years of age; 30% vs 13%; P = .02) or married (31% vs 17%; P = .04). Choice of surgery did not differ significantly by other clinical characteristics (P values > .16). Among younger patients (< 60 years), those who were married were more likely to choose mastectomy over BCT (37% vs 18%; P = .04), while those who were not married were equally likely to choose mastectomy or BCT (25% vs 21%; P = .65).

Within the group of 29 patients who chose mastectomy, 55% underwent breast reconstruction and 40% underwent prophylactic contralateral mastectomy. Postmastectomy radiation was recommended in 21% of these patients, based on pathologic findings at the time of surgery.

Conclusions: Of the patients who were eligible for BCT, younger age and being married were associated with choosing mastectomy. MRI findings alone resulted in 7% of patients initially eligible for breast conservation no longer being eligible for breast conservation. Also, 21% of patients who chose mastectomy required adjuvant radiation therapy.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Related Content